Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Hutchmed China Ltd ADR (NQ: HCM )

19.81 +1.00 (+5.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 170,483
Open 19.40
Bid (Size) 19.53 (1)
Ask (Size) 21.36 (1)
Prev. Close 18.81
Today's Range 19.27 - 19.99
52wk Range 11.93 - 21.92
Shares Outstanding 871,256,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
From HUTCHMED (China) Limited
Via GlobeNewswire
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety

Performance

YTD
+13.14%
+13.14%
1 Month
+19.84%
+19.84%
3 Month
+6.22%
+6.22%
6 Month
+18.76%
+18.76%
1 Year
+5.48%
+5.48%

More News

Read More
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
From HUTCHMED (China) Limited
Via GlobeNewswire
Hutchmed scores U.S. success with cancer drug, but profits still dip
Via Benzinga
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
Why HUTCHMED Stock Is Moving Higher Friday
Via Benzinga
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2024 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
From HUTCHMED (China) Limited
Via GlobeNewswire
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
Via Benzinga
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.